Subcutaneous and intranasal administration of 1-deamino-8-d-arginine vasopressin in the assessment of renal concentration capacity

Research output: Contribution to journalArticle

Abstract

Maximum urine concentration capacity was studied in healthy adults using different routes and doses of administration of 1-deamino-8-d-arginine vasopressin (DDAVP) - desmopressin. Plasma levels of DDAVP showed a dose-dependent increase after the subcutaneous but not after the intranasal administration. The effect on urine osmolality was similar but more prolonged after the subcutaneous as compared to the intranasal route. We conclude that subcutaneous injection is a simple and reliable way of administering DDAVP. A dose of 4 μg in adults is optimum diagnostically and it corresponds to 20-40 μg administered intranasally.

Details

Authors
Organisations
External organisations
  • Skåne University Hospital
  • Central Hospital Kristianstad
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Urology and Nephrology
Original languageEnglish
Pages (from-to)27-30
JournalNephron
Volume45
Issue number1
Publication statusPublished - 1987
Publication categoryResearch
Peer-reviewedYes